MedTrace Logo

Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period

NCT00614536 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1142

Last updated 2014-04-28

No results posted yet for this study

Summary

The purpose of this observational study is to examine RSI (Reflux Symptom Index) and RFS (Reflux Finding Score) by treatment period before and after rabeprazole treatment in LaryngoPharyngeal Reflux Disease(LPRD) patients.

Conditions

  • Gastroesophageal Reflux
  • Pharyngeal Diseases

Interventions

DRUG

Rabeprazole Sodium

10mg - 20mg tablet once or twice daily for 12weeks

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-04-30
Completion
2008-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614536 on ClinicalTrials.gov